Pavan P. Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pavan P. Shah has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Adrian E. Jimenez
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2 shared publications Chetan Bettegowda
Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2 shared publications- Debraj Mukherjee
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2 shared publications Gary Gallia
Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2 shared publicationsHenry Brem
Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2 shared publicationsJon Weingart
Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2 shared publications
Latest Publications
- 14 September 2022
- Published by Elsevier in World Neurosurgery
- Vol. 167, e1291-e1298
A Potential Role for Steroids in Acute Pain Management in Patients with Trigeminal Neuralgia
- 14 September 2022
- Published by Elsevier in World Neurosurgery
- Vol. 167, e1291-e1298
A Potential Role for Steroids in Acute Pain Management in Patients with Trigeminal Neuralgia
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S183
Circulating Coagulation Regulator Levels After Lung Transplantation Are Associated with Acute Kidney Injury
- 7 April 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (4) , S183
Circulating Coagulation Regulator Levels After Lung Transplantation Are Associated with Acute Kidney Injury
- 1 March 2022
- Published by Elsevier in World Neurosurgery
- Vol. 159, e130-e138
Predicting High-Value Care Outcomes After Surgery for Non–Skull Base Meningiomas
- 1 March 2022
- Published by Elsevier in World Neurosurgery
- Vol. 159, e130-e138
Predicting High-Value Care Outcomes After Surgery for Non–Skull Base Meningiomas
- 1 September 2021
- Published by Elsevier in World Neurosurgery
- Vol. 153, e338-e348
Patient-Specific Factors Drive Intensive Care Unit and Total Hospital Length of Stay in Operative Patients with Brain Tumor
- 1 September 2021
- Published by Elsevier in World Neurosurgery
- Vol. 153, e338-e348
Patient-Specific Factors Drive Intensive Care Unit and Total Hospital Length of Stay in Operative Patients with Brain Tumor
- Open Access
- 1 April 2021
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 40 (4) , S318
Telemedicine with a Cell-Free DNA Based Monitoring Approach Maintains Lung Allograft Function While Reducing Frequency of Invasive Bronchoscopy
- 1 April 2021
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 40 (4) , S318
Open AccessTelemedicine with a Cell-Free DNA Based Monitoring Approach Maintains Lung Allograft Function While Reducing Frequency of Invasive Bronchoscopy
- 1 October 2019
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 5 (10) , 1497-1498
Weakness and Myalgia in a Patient With Hepatocellular Carcinoma Undergoing Checkpoint Inhibitor Therapy
A man in his 50s with nonalcoholic steatohepatitis and hepatocellular carcinoma undergoing checkpoint inhibitor therapy experiences weakness and myalgia. What i
- 1 October 2019
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 5 (10) , 1497-1498
Weakness and Myalgia in a Patient With Hepatocellular Carcinoma Undergoing Checkpoint Inhibitor Therapy
A man in his 50s with nonalcoholic steatohepatitis and hepatocellular carcinoma undergoing checkpoint inhibitor therapy experiences weakness and myalgia. What i
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , e13530
The role of postradiation temozolomide in patients with newly diagnosed MGMT methylated glioblastoma.
E13530 Background: Standard therapy for patients with newly diagnosed glioblastoma (GBM) includes concurrent temozolomide (TMZ) and radiation (RT) followed by six monthly cycles of adjuvant TMZ. Although TMZ improves survival for MGMT methylated patients, it is unclear if this benefit is from the TMZ given with the radiation, the adjuvant TMZ, or if both are required. This retrospective study was designed to identify MGMT methylated patients who started treatment with near-normal functional status, completed concurrent RT+TMZ, but did not receive adjuvant TMZ to estimate if their survival was significantly less than expected. Methods: We reviewed charts from 190 adults diagnosed with GBM at Johns Hopkins Hospital from 2013 to 2015 recording their Karnofsky Performance Score (KPS), extent of resection, MGMT-methylation and IDH1 mutation status, and treatment records. We selected patients with MGMT-methylated GBM who received concurrent RT+TMZ without adjuvant TMZ for this study. Patients with a KPS < 70 or severe post-radiation complications were excluded. Results: Six patients met the selection criteria. They had a median age of 65 years, average KPS of 80, 2/6 had a gross total resection, and all were IDH1 wildtype. Their overall survival ranged from 17 to > 46 months. Conclusions: The overall survival of these patients who received no adjuvant TMZ is very similar to the median of 23 months reported in the literature for MGMT methylated patients who received adjuvant TMZ. This preliminary data suggests that a prospective study in MGMT methylated patients comparing concurrent RT+TMZ followed by either standard adjuvant TMZ or observation could be considered without placing patients in the experimental arm at excessive risk.[Table: see text]
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , e13530
The role of postradiation temozolomide in patients with newly diagnosed MGMT methylated glioblastoma.
E13530 Background: Standard therapy for patients with newly diagnosed glioblastoma (GBM) includes concurrent temozolomide (TMZ) and radiation (RT) followed by six monthly cycles of adjuvant TMZ. Although TMZ improves survival for MGMT methylated patients, it is unclear if this benefit is from the TMZ given with the radiation, the adjuvant TMZ, or if both are required. This retrospective study was designed to identify MGMT methylated patients who started treatment with near-normal functional status, completed concurrent RT+TMZ, but did not receive adjuvant TMZ to estimate if their survival was significantly less than expected. Methods: We reviewed charts from 190 adults diagnosed with GBM at Johns Hopkins Hospital from 2013 to 2015 recording their Karnofsky Performance Score (KPS), extent of resection, MGMT-methylation and IDH1 mutation status, and treatment records. We selected patients with MGMT-methylated GBM who received concurrent RT+TMZ without adjuvant TMZ for this study. Patients with a KPS < 70 or severe post-radiation complications were excluded. Results: Six patients met the selection criteria. They had a median age of 65 years, average KPS of 80, 2/6 had a gross total resection, and all were IDH1 wildtype. Their overall survival ranged from 17 to > 46 months. Conclusions: The overall survival of these patients who received no adjuvant TMZ is very similar to the median of 23 months reported in the literature for MGMT methylated patients who received adjuvant TMZ. This preliminary data suggests that a prospective study in MGMT methylated patients comparing concurrent RT+TMZ followed by either standard adjuvant TMZ or observation could be considered without placing patients in the experimental arm at excessive risk.[Table: see text]
- 1 July 2017
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (13_Supplem) , 3731
Abstract 3731: A novel multidimensional cfDNA assay for real time analysis of chemotherapy response
Due to its non-invasive nature and transient lifespan (~30 mins), circulating cell free DNA (cfDNA) may provide novel insights into cancer evolution and response to therapy. Here, we have developed a multidimensional cfDNA assay to measure patients’ responses to chemotherapy on a time scale that would be impossible using traditional biopsy methodologies. We extracted cfDNA from plasma collected immediately before and after infusion of cytotoxic chemotherapy, and 24 hours after treatment. We developed assays to (1) quantify cfDNA via qPCR of a 288 base pair amplicon of Long Interspersed Nuclear Elements (LINE1), (2) determine the DNA Integrity Index based on additional analysis of 115bp and 516bp LINE1 amplicons, and (3) analyze androgen receptor exon 8 via targeted deep sequencing. We analyzed cfDNA extracted from 17 patients with metastatic castration-resistant prostate cancer through sequential application of these 3 assays. Median PSA levels were 69 (0-2223) ng/dl, Hgb 12 (8.2-15) g/L, Alk Phos 117 (35-879) IU/mL. Deep sequencing of AR exon 8 revealed 6 of the 17 patients presented with 1-2 SNVs (H874Y, T877A, D890H or D879Y) at ≥1% frequency. Considering LINE1 quantification alone, the average change pre/post chemotherapy was 38.78 pg/mL (0.5-292.0 pg/mL). A variety of responses was noted including: 8 of the patients expressed elevated LINE1 levels post-treatment when compared to baseline, and 5 expressed depressed levels. Importantly, therapy did not affect tumor subclones equally, as demonstrated by sequencing and quantitation of mutant AR exon 8 species. Additional data on changes in DNA Integrity Index will be presented. We conclude that cytotoxic chemotherapy produces immediately observable effects on cfDNA. The effect of docetaxel chemotherapy on distinct clones within the tumor can be measured within hours. Now that a short-time dynamics response has been demonstrated, follow up studies will be performed involving more patients to determine the prognostic value. Citation Format: Pavan P. Shah, Katherin Patsch, Naim Matasci, Anjana Soudararajan, Patricia Diaz, David B. Agus, Daniel Ruderman, Mitchell E. Gross. A novel multidimensional cfDNA assay for real time analysis of chemotherapy response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3731. doi:10.1158/1538-7445.AM2017-3731
- 1 July 2017
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (13_Supplem) , 3731
Abstract 3731: A novel multidimensional cfDNA assay for real time analysis of chemotherapy response
Due to its non-invasive nature and transient lifespan (~30 mins), circulating cell free DNA (cfDNA) may provide novel insights into cancer evolution and response to therapy. Here, we have developed a multidimensional cfDNA assay to measure patients’ responses to chemotherapy on a time scale that would be impossible using traditional biopsy methodologies. We extracted cfDNA from plasma collected immediately before and after infusion of cytotoxic chemotherapy, and 24 hours after treatment. We developed assays to (1) quantify cfDNA via qPCR of a 288 base pair amplicon of Long Interspersed Nuclear Elements (LINE1), (2) determine the DNA Integrity Index based on additional analysis of 115bp and 516bp LINE1 amplicons, and (3) analyze androgen receptor exon 8 via targeted deep sequencing. We analyzed cfDNA extracted from 17 patients with metastatic castration-resistant prostate cancer through sequential application of these 3 assays. Median PSA levels were 69 (0-2223) ng/dl, Hgb 12 (8.2-15) g/L, Alk Phos 117 (35-879) IU/mL. Deep sequencing of AR exon 8 revealed 6 of the 17 patients presented with 1-2 SNVs (H874Y, T877A, D890H or D879Y) at ≥1% frequency. Considering LINE1 quantification alone, the average change pre/post chemotherapy was 38.78 pg/mL (0.5-292.0 pg/mL). A variety of responses was noted including: 8 of the patients expressed elevated LINE1 levels post-treatment when compared to baseline, and 5 expressed depressed levels. Importantly, therapy did not affect tumor subclones equally, as demonstrated by sequencing and quantitation of mutant AR exon 8 species. Additional data on changes in DNA Integrity Index will be presented. We conclude that cytotoxic chemotherapy produces immediately observable effects on cfDNA. The effect of docetaxel chemotherapy on distinct clones within the tumor can be measured within hours. Now that a short-time dynamics response has been demonstrated, follow up studies will be performed involving more patients to determine the prognostic value. Citation Format: Pavan P. Shah, Katherin Patsch, Naim Matasci, Anjana Soudararajan, Patricia Diaz, David B. Agus, Daniel Ruderman, Mitchell E. Gross. A novel multidimensional cfDNA assay for real time analysis of chemotherapy response [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3731. doi:10.1158/1538-7445.AM2017-3731